دورية أكاديمية
أعرض في EDS

Celiac plexus neurolysis for abdominal cancers: going beyond pancreatic cancer pain.

التفاصيل البيبلوغرافية
العنوان: Celiac plexus neurolysis for abdominal cancers: going beyond pancreatic cancer pain.
المؤلفون: Ambai VT; Department of Graduate Medical Education - Transitional Year Residency Program, Northside Hospital - Gwinnett, Lawrenceville, GA, USA., Singh V; Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA, USA., Boorman DW; Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA, USA., Neufeld NJ; Department of Pain and Palliative Care, Cancer Treatment Centers of America, Newnan, GA, USA.
المصدر: Pain reports [Pain Rep] 2021 May 12; Vol. 6 (1), pp. e930. Date of Electronic Publication: 2021 May 12 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wolters Kluwer Country of Publication: United States NLM ID: 101683899 Publication Model: eCollection Cited Medium: Internet ISSN: 2471-2531 (Electronic) Linking ISSN: 24712531 NLM ISO Abbreviation: Pain Rep Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Baltimore, MD : Wolters Kluwer, [2016]-
مستخلص: Introduction: Celiac plexus neurolysis (CPN) has been verified for mitigating pancreatic cancer pain. However, information regarding CPN's use beyond this remains limited.
Objectives: Identify which cancers benefit from CPN, which symptoms improve, and when symptoms improve.
Methods: Retrospective analysis was conducted on 173 patients who received CPN for pain caused by various malignancies. Mean symptom changes on the MD Anderson Symptom Inventory (MDASI) from baseline to 2 weeks, 1 month, and 2 months after CPN were analyzed overall and then by cancer type: pancreatic (all stages and stages III-IV), hepatobiliary, and nonpancreatic, nonhepatobiliary gastrointestinal (NPNH-gastrointestinal).
Results: Eighty-two pancreatic, 43 NPNH-gastrointestinal, 14 hepatobiliary, and 34 patients with other cancers met inclusion criteria. Statistically significant changes included decrease in the pain score at 1 month by 1.01 points for all cancers, 1.65 points for all pancreatic cancers, and 1.88 points for late-stage pancreatic cancers. At 2 months, pain decreased by 1.50 points for all cancers, 1.68 points for all pancreatic cancers, 2.37 points for late-stage pancreatic cancers, and 1.50 points in NPNH-gastrointestinal cancers. At 2 months, quality of life improved by 1.07 points for all cancers and 1.53 points for all pancreatic cancers. Sleep improved at 2 months for all cancers by 0.73 points and 1.60 points in late-stage pancreatic cancers. At 2 months, pancreatic cancer patients improved in general activity by 0.93 points, walking by 1.00 points, and working by 1.12 points.
Conclusion: Celiac plexus neurolysis can decrease cancer symptom burden beyond pain including quality of life and sleep for pancreatic and nonpancreatic cancers, as well as general activity for pancreatic cancers.
Competing Interests: Dr. Vinita Singh is a consultant for Releviate LLC. The remaining authors have no conflicts of interest to declare. Dr. V. Singh is a KL2 scholar at the Georgia, Clinical, and Translational Science Alliance and would like to acknowledge that this article was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award number ULTR002378 and KL2TR002381. The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
(Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain.)
References: Anesth Analg. 1995 Feb;80(2):290-5. (PMID: 7818115)
Semin Intervent Radiol. 2017 Dec;34(4):376-386. (PMID: 29249862)
Pain Med. 2001 Mar;2(1):28-34. (PMID: 15102315)
Support Care Cancer. 2018 Jun;26(6):2023-2030. (PMID: 29344736)
Sleep. 2007 Jun;30(6):737-42. (PMID: 17580595)
Spine J. 2018 Feb;18(2):261-267. (PMID: 28713049)
Cochrane Database Syst Rev. 2017 Jul 06;7:CD012592. (PMID: 28683172)
Pancreatology. 2009;9(6):755-63. (PMID: 20090396)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
J Patient Rep Outcomes. 2019 Jun 17;3(1):34. (PMID: 31209661)
Pain. 2004 Jul;110(1-2):400-8. (PMID: 15275792)
Gastroenterology. 2019 Jan;156(1):254-272.e11. (PMID: 30315778)
Pain Med. 2013 Aug;14(8):1140-63. (PMID: 23802777)
J Pain Palliat Care Pharmacother. 2005;19(3):15-20. (PMID: 16219607)
Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007519. (PMID: 21412903)
JAMA. 2004 Mar 3;291(9):1092-9. (PMID: 14996778)
J Gastrointestin Liver Dis. 2013 Mar;22(1):59-64. (PMID: 23539392)
Curr Treat Options Oncol. 2008 Jun;9(2-3):234-41. (PMID: 18712483)
Brain Behav Immun. 2013 Mar;30 Suppl:S58-67. (PMID: 22634367)
Ann Surg Oncol. 2011 Mar;18(3):636-41. (PMID: 20953910)
Pain Med. 2015 Sep 9;17(5):892-898. (PMID: 26352991)
Clin Anat. 2010 Jul;23(5):512-22. (PMID: 20235178)
فهرسة مساهمة: Keywords: Cancer pain; Celiac plexus neurolysis; Gastrointestinal cancer; Hepatobiliary cancer; Pancreatic cancer; Quality of life
تواريخ الأحداث: Date Created: 20211029 Latest Revision: 20220427
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8546843
DOI: 10.1097/PR9.0000000000000930
PMID: 34712884
قاعدة البيانات: MEDLINE
الوصف
تدمد:2471-2531
DOI:10.1097/PR9.0000000000000930